Did you know?
ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.
Free Newsletter
Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!
Free Report
I-Mab to Test Anti-Inflammatory for Cytokine Release Syndrome in COVID-19 Patients
I-Mab (NSDQ: IMAB), a Shanghai clinical-stage biopharma, has started to develop TJM2 (TJ003234) to treat cytokine release syndrome in severe cases of COVID-19. TJM2 is an I-Mab-discovered neutralizing antibody that binds human granulocyte-macrophage colony stimulating factor (GM-CSF), an important cytokine that plays a critical role in acute and chronic inflammation. By binding GM-CSF, TJM2 prevents downstream signaling and target cell activation, inhibiting other inflammatory responses. I-Mab intends to start clinical trials upon US acceptance of its IND. The company will expand the trials to countries especially hard-hit by COVID-19.
I-Mab said GM-CSF can polarize macrophages into the pro-inflammatory M1 phenotype and is known to induce an inflammatory cascade involving other pro-inflammatory cytokines such as tumor-necrosis factor (TNF), interleukin-1 (IL-1), IL-6, IL-12, and IL-23.
Cytokine storm is characterized by a surge in levels of circulating inflammatory cytokines, and is an overreaction of the immune system under conditions that include CAR-T therapy and patients infected with SARS-CoV-2. Recent studies revealed that high levels of GM-CSF, along with a few other cytokines, are critically associated with severe clinical complications in COVID-19 patients, especially the 20% of all patients whose disease requires intensive care.
I-Mab has completed a Phase I single ascending dose (SAD) study of TJM2 in the United States, in which TJM2 exhibited favorable safety, tolerability, PK/PD, and immunogenicity profiles. TJM2 also received IND clearance in China for a multiple-dose Phase Ib study in patients with rheumatoid arthritis (RA). The results from the planned COVID-19 study will also be used to further evaluate the potential therapeutic role of TJM2 in reducing or preventing cytokine storm and neurotoxicity associated with CAR-T therapy.
“Research data provide the rationale to use TJM2 as a potential treatment for cytokine storm associated with COVID-19, because the antibody effectively neutralizes circulating GM-CSF to control acute inflammatory responses, and it may also exhibit potential advantages over conventional IL-6 antibodies, ” said Dr. Joan Shen, CEO of I-Mab. “This expanded IND application of TJM2 would allow us to act timely to help battle the global COVID-19 pandemic.”
See our other articles on I-Mab.
ChinaBio® News
Greg Scott Interviewed at BIO-Europe Spring
How to bring your China assets to China in 8 minutes
"Mr. Bio in China."
Mendelspod Interview
Multinational pharma held to a higher standard in China